Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06006325
Other study ID # NKYY_YXKT_IRB_2022_023_01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 20, 2023
Est. completion date October 2, 2024

Study information

Verified date March 2024
Source Tianjin Nankai Hospital
Contact Jianbo Yu, MD
Phone +8615344422323
Email 30717008@nankai.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this interventional clinical trial, researchers will administer electroacupuncture versus sham electroacupuncture to sepsis patients with ARDS and collect objective outcome measures. The study will be divided into 2 groups. The EA group will receive electroacupuncture and the SHAM-EA group will receive sham electroacupuncture. The purpose of this study is to investigate the effect of electroacupuncture on the synthesis of SPMs in sepsis patients with ARDS.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date October 2, 2024
Est. primary completion date July 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Males or females over the age of 18; 2. Diagnosis meets SPESIS 3 criteria for sepsis; 3. The diagnosis meets the Berlin diagnostic criteria for ARDS; 4. ARDS was diagnosed within 48h; 5. Capable of understanding the purpose and risk of the study; 6. Patients or proxy must give written informed consent before any assessment is performed. Exclusion Criteria: 1. ARDS was diagnosed 48h later; 2. Pregnancy, lactation or perinatal period; 3. malignant tumor; 4. Severe liver failure or kidney failure; 5. Predicted mortality risk of patients within 24h>80%; 6. Severe end-stage lung disease; 7. ECMO patients are undergoing implementation; 8. HIV seropositive or Syphilis seropositive; 9. Any clinical-relevant condition that might affect study participation and/or study results; 10. Participation in any other intervention trial; 11. Unwillingness or inability to following the study protocol in the investigators opinion.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
electroacupuncture treatment
Patients received acupuncture on both sides of the Zusanli (ST36) acupuncture points, and after "Deqi ", the needle was connected to an electro-acupuncture device (Hwato, Suzhou Medical ). The EA stimulation lasted for 30 min.
sham electroacupuncture treatment
The participants in the SHAM-EA group performed shallow punctures at the bilateral non-acupuncture points, did not perform the "Deqi" operation, and were connected to the electroacupuncture stimulator but not energized.

Locations

Country Name City State
China Tianjin Nankai Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Nankai Hospital

Country where clinical trial is conducted

China, 

References & Publications (4)

Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018 Jul 7;392(10141):75-87. doi: 10.1016/S0140-6736(18)30696-2. Epub 2018 Jun 21. — View Citation

Faix JD. Biomarkers of sepsis. Crit Rev Clin Lab Sci. 2013 Jan-Feb;50(1):23-36. doi: 10.3109/10408363.2013.764490. — View Citation

Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, Fisher B, Thacker LR 2nd, Natarajan R, Brophy DF, Sculthorpe R, Nanchal R, Syed A, Sturgill J, Martin GS, Sevransky J, Kashiouris M, Hamman S, Egan KF, Hastings A, Spencer W, Tench S, Mehkri O, Bindas J, Duggal A, Graf J, Zellner S, Yanny L, McPolin C, Hollrith T, Kramer D, Ojielo C, Damm T, Cassity E, Wieliczko A, Halquist M. Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA. 2019 Oct 1;322(13):1261-1270. doi: 10.1001/jama.2019.11825. Erratum In: JAMA. 2020 Jan 28;323(4):379. — View Citation

Liu S, Wang Z, Su Y, Qi L, Yang W, Fu M, Jing X, Wang Y, Ma Q. A neuroanatomical basis for electroacupuncture to drive the vagal-adrenal axis. Nature. 2021 Oct;598(7882):641-645. doi: 10.1038/s41586-021-04001-4. Epub 2021 Oct 13. Erratum In: Nature. 2022 Jan;601(7893):E9. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Serum levels of Lipoxin A4 (LXA4) Serum levels of LXA4 were measured in post-intervention patients and levels were compared to Day 0. Up to 7 days
Secondary LXA4 levels in BALF LXA4 levels were measured in the BALF of patients after the intervention and the levels were compared to day 0. Up to 7 days
Secondary Ventilation-free days The number of days the patient was alive and free of mechanical ventilation (MV) Up to 28 days
Secondary Oxygenation index The ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage). Up to 7 days
Secondary Ventilator-provided positive end-expiratory pressure (PEEP) Ventilator parameter Up to 7 days
Secondary plateau pressure Ventilator parameter Up to 7 days
Secondary tidal volume Ventilator parameter Up to 7 days
Secondary Inflammation biomarkers Inflammation levels Procalcitonin (PCT), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1ß), and interleukin-6 (IL-6) Up to 7 days
Secondary Sequential Organ-Failure Assessment (SOFA) score The SOFA score is used to assess the severity and prognosis of sepsis.SOFA was based on six different scores, one for each of the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems each scored from 0 to 4 with an increasing score reflecting worsening organ dysfunction. Up to 7 days
Secondary Rate of electroacupuncture-related adverse events Rate of electroacupuncture-related adverse events Up to 28 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3